| Administration route |
intravenous infusion |
| Dosage |
0.6E6 cells/kg, 2E6 cells/kg |
| Pts |
9 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
9/9(CR,1 month) |
| Adverse reactions |
CAR-T-related adverse events occurred in 9 patients(9/9, 100%), no adverse events leading to patient withdrawal from the study occurred. 8 patients(8/9, 89%) experienced cytokine release syndrome(CRS), including 5(5/9, 56%) grade 1, 3(3/9, 33%) grade 2, and no grade 3 or higher CRS occurred. Two patients(2/9, 22%) experienced immune effector cell-associated neurotoxicity syndrome(ICANS), including 1(1/9, 11%) grade 1, 1(1/9, 11%) grade 2, and no grade 3 or higher ICANS occurred. |
| References |
DOI:
10.1182/blood-2022-162134
|
|